Iceland· IS-EU/1/25/1917/002
Lynozyfic
A other monoclonal antibodies and antibody drug conjugates product containing linvoseltamab, registered in Iceland by Regeneron Ireland Designated Activity Company. The same ATC class is registered in 5 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Linvoseltamab is registered in 5 of 19 countries.
Countries holding a registration under ATC L01FX (other monoclonal antibodies and antibody drug conjugates), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 4 of them publish a price we can compare per daily dose
Linvoseltamab · ATC L01FX
5 / 19 countries
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Linvoseltamab
- Manufacturer
- Regeneron Ireland Designated Activity Company
- Country
- Iceland (IS)
- ATC code
- L01FX
- ATC class
- Other monoclonal antibodies and antibody drug conjugates
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linvoseltamab in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumLynozyfic 200 mgRegeneron Ireland Designated Activity Company (DAC)
- CzechiaLYNOZYFICRegeneron Ireland Designated Activity Company, Dublin
- FinlandLYNOZYFICRegeneron Ireland Designated Activity Company (DAC)
- IrelandLYNOZYFIC 200 mg concentrate for solution for infusionRegeneron Ireland Designated Activity Company
- SwedenLYNOZYFIC 200 mg Koncentrat till infusionsvätska, lösningRegeneron Ireland Designated Activity Company
- SpainLYNOZYFIC 200 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRegeneron Ireland Designated Activity Company
- United StatesLYNOZYFICRegeneron Pharmaceuticals, Inc.
- NetherlandsLYNOZYFIC 200 mg concentraat voor oplossing voor infusieRegeneron Ireland Designated Activity Company
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Lynozyfic
- Norway · Lynozyfic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b1628646-e3f1-4e08-b186-b6866b1d10ff GET /v1/drugs/b1628646-e3f1-4e08-b186-b6866b1d10ff?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FX",
"marketed": false,
"strength": "200 mg",
"ma_number": "EU/1/25/1917/002",
"substance": "Linvoseltamab",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45770"
}See everything about linvoseltamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.